GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Biogen Inc (HAM:IDP) » Definitions » Shiller PE Ratio

Biogen (HAM:IDP) Shiller PE Ratio : 10.88 (As of May. 20, 2024)


View and export this data going back to 2001. Start your Free Trial

What is Biogen Shiller PE Ratio?

As of today (2024-05-20), Biogen's current share price is €211.70. Biogen's E10 for the quarter that ended in Mar. 2024 was €19.45. Biogen's Shiller PE Ratio for today is 10.88.

The historical rank and industry rank for Biogen's Shiller PE Ratio or its related term are showing as below:

HAM:IDP' s Shiller PE Ratio Range Over the Past 10 Years
Min: 9.23   Med: 29.75   Max: 110.75
Current: 10.94

During the past years, Biogen's highest Shiller PE Ratio was 110.75. The lowest was 9.23. And the median was 29.75.

HAM:IDP's Shiller PE Ratio is ranked better than
86.7% of 534 companies
in the Drug Manufacturers industry
Industry Median: 24.98 vs HAM:IDP: 10.94

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Biogen's adjusted earnings per share data for the three months ended in Mar. 2024 was €2.484. Add all the adjusted EPS for the past 10 years together and divide 10 will get our E10, which is €19.45 for the trailing ten years ended in Mar. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


Biogen Shiller PE Ratio Historical Data

The historical data trend for Biogen's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biogen Shiller PE Ratio Chart

Biogen Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 21.24 15.16 13.53 13.69 12.51

Biogen Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 13.49 13.58 12.33 12.51 10.23

Competitive Comparison of Biogen's Shiller PE Ratio

For the Drug Manufacturers - General subindustry, Biogen's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Biogen's Shiller PE Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Biogen's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Biogen's Shiller PE Ratio falls into.



Biogen Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Biogen's Shiller PE Ratio for today is calculated as

Shiller PE Ratio=Share Price/ E10
=211.70/19.45
=10.88

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Biogen's E10 for the quarter that ended in Mar. 2024 is calculated as:

For example, Biogen's adjusted earnings per share data for the three months ended in Mar. 2024 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=2.484/131.7762*131.7762
=2.484

Current CPI (Mar. 2024) = 131.7762.

Biogen Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201406 2.215 100.560 2.903
201409 2.809 100.428 3.686
201412 3.033 99.070 4.034
201503 3.225 99.621 4.266
201506 3.502 100.684 4.583
201509 3.698 100.392 4.854
201512 3.461 99.792 4.570
201603 3.978 100.470 5.218
201606 4.263 101.688 5.524
201609 4.197 101.861 5.430
201612 2.835 101.863 3.668
201703 3.235 102.862 4.144
201706 3.622 103.349 4.618
201709 4.858 104.136 6.147
201712 -1.191 104.011 -1.509
201803 4.493 105.290 5.623
201806 3.578 106.317 4.435
201809 6.128 106.507 7.582
201812 4.158 105.998 5.169
201903 6.328 107.251 7.775
201906 6.947 108.070 8.471
201909 7.618 108.329 9.267
201912 7.272 108.420 8.839
202003 7.312 108.902 8.848
202006 8.516 108.767 10.317
202009 3.787 109.815 4.544
202012 1.907 109.897 2.287
202103 2.260 111.754 2.665
202106 2.482 114.631 2.853
202109 1.887 115.734 2.149
202112 2.213 117.630 2.479
202203 1.870 121.301 2.031
202206 6.849 125.017 7.219
202209 7.918 125.227 8.332
202212 3.578 125.222 3.765
202303 2.494 127.348 2.581
202306 3.757 128.729 3.846
202309 -0.440 129.860 -0.446
202312 1.568 129.419 1.597
202403 2.484 131.776 2.484

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Biogen  (HAM:IDP) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Biogen Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Biogen's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Biogen (HAM:IDP) Business Description

Address
225 Binney Street, Cambridge, MA, USA, 02142
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel multiple sclerosis drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is copromoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with Sobi) were spun off as part of Bioverativ in 2017. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (post-partum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology-related fields.

Biogen (HAM:IDP) Headlines

No Headlines